预约演示
更新于：2025-09-16
Labetalol Hydrochloride
盐酸拉贝洛尔
更新于：2025-09-16
概要
基本信息
药物类型 小分子化药 |
别名 拉贝洛尔、AH-5158A、AH-5158A HYDROCHLORIDE + [11] |
作用方式 拮抗剂 |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1982-10-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O3 |
InChIKeyWQVZLXWQESQGIF-UHFFFAOYSA-N |
CAS号32780-64-6 |
关联
106
项与 盐酸拉贝洛尔 相关的临床试验CTR20252607
盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
PACTR202504557828315
Intravenous Labetalol Versus Oral Nifedipine in The Control of Blood pressure in Severe Hypertensive disorders of Pregnancy: A Randomised Controlled Trial
CTR20250958
盐酸拉贝洛尔片（200mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验
100 项与 盐酸拉贝洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的专利（医药）
登录后查看更多信息
3,599
项与 盐酸拉贝洛尔 相关的文献（医药）2025-12-31Journal of Maternal-Fetal & Neonatal Medicine
Evaluation of fetal outcomes in dichorionic diamniotic twins with hypertensive disorders during pregnancy by the fetal middle cerebral artery and umbilical artery doppler
Article
作者: Lin, Xin ; Xu, Hai-hua ; Liu, Ling-ling
BACKGROUND:
Hypertensive disorders of pregnancy (HDP) is associated with the poor prognosis of dichorionic diamniotic (DCDA) twins. The prediction value of middle cerebral artery (MCA) and umbilical artery (UA) Doppler indices requires exploration.
OBJECTIVE:
To investigate the significance of the fetal MCA and UA doppler indices in DCDA fetal outcomes and depict hemodynamic alterations.
METHODS:
DCDA twin pregnancies were classified into the normotensive control group (n = 177) and the HDP group [n = 189, with 60 gestational hypertensions (GH) and 129 preeclampsia/eclampsia (PE/EC)]. Maternal and fetal outcomes were compared, the fetal MCA and UA doppler indices were analyzed, including pulsatility index (PI), resistance index (RI), the ratio of peak systolic blood flow velocity to end-diastolic blood flow velocity (S/D), and the mean velocities (Vm), and the cerebroplacental ratio (CPR) was computed for further study. The receiver operating characteristic curve was used to predict and evaluate small for gestational age (SGA) neonates in HDP twin pregnancies.
RESULTS:
Significant differences were shown between the HDP group and the normotensive control group in terms of maternal age, gestational weight gain, blood pressure, post 20-week urinary protein, the use of maternal medication utilization (magnesium sulfate, labetalol, dexamethasone), inter-twin growth discordance, and SGA (p < 0.05). In DCDA twins, the fetal MCA doppler indices (PI, RI and S/D) increased initially and then declined, UA indices (PI, RI and S/D) were declining, and both the Vm of MCA and UA were going up. In late DCDA twin pregnancies with GH, UA Doppler moderately predicted SGA neonates; in those with PE/EC, CPR did the same values (p < 0.05).
CONCLUSION:
In DCDA pregnancies complicated by hypertensive disorders, SGA twins exhibit distinct doppler deterioration patterns. Implementing customized monitoring strategies based on the fetal MCA and UA indices can effectively predict adverse conditions, enable timely interventions, and ensure fetal health.
2025-11-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Risk of postpartum readmission following discharge on nifedipine or labetalol for hypertensive disorders of pregnancy: A systematic review and meta-analysis
Review
作者: Ortiz, Vanessa ; Kanninen, Tomi ; Haddad, Andrew ; Alvarez, Manuel ; Al-Khan, Abdulla ; Alvarez-Perez, Jesus
OBJECTIVES:
To examine if the postpartum readmission rate was influenced by the use of nifedipine compared with labetalol at discharge in patients with hypertensive disorders of pregnancy.
STUDY DESIGN:
PubMed, ClinicalTrials.gov, Science Direct and the Cochrane Central Register of Controlled Trials were searched from inception to September 2024.All studies comparing the readmission rate following use of nifedipine vs labetalol after postpartum discharge in patients with hypertensive disorders of pregnancy were identified. Risk of bias was assessed according to the Newcastle-Ottawa Scale.
RESULTS:
Four studies were identified, representing 13,628 patients in the nifedipine group and 23,348 patients in the labetalol group. Study quality was judged to be good. The readmission rate was significantly lower when patients were discharged on nifedipine compared with labetalol [RR 0.41, 95% confidence interval (CI) 0.33-0.52]. Furthermore, the readmission rate specifically for hypertensive complications was significantly lower in patients discharged on nifedipine compared with labetalol (RR 0.36, 95% CI 0.23-0.56). The readmission rate for all causes did not differ significantly between patients discharged on nifedipine compared with labetalol (RR 0.69, 95% CI 0.33-1.43). Robustness of these findings were confirmed through sensitivity analysis.
CONCLUSION:
Discharge on nifedipine for management of hypertensive disorders of pregnancy was associated with a significantly lower readmission rate for hypertensive complications compared with discharge on labetalol.
2025-10-01JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY
Differences in Outcomes for Patients Receiving Labetalol and Nicardipine for Hypertension After Craniotomy
Article
作者: Torjman, Marc ; Sun, George ; Min, Kevin J. ; Owrey, Matthew
Background::
Acute postoperative hypertension (APH) is encountered in patients following craniotomy and is associated with major complications. This retrospective cohort study evaluates 30-day survival for patients who received labetalol, nicardipine, or both drugs.
Methods::
Patients 18 and older who underwent craniotomy between January 1, 2010 and January 1, 2023 were included in the study. Analyses were performed comparing (1) labetalol cohort versus nicardipine cohort, (2) labetalol cohort versus both cohort, and (3) nicardipine cohort versus both cohort. The primary outcome was survival at 30 days. Secondary outcomes included 30-day readmission, ST-elevation myocardial infarction (STEMI), congestive heart failure (CHF), non-ST elevation myocardial infarction (NSTEMI), arrhythmia, and intracranial hemorrhage.
Results::
The labetalol cohort had improved 30-day survival compared with the nicardipine cohort (HR: 0.49, P<0.0001) or both (HR: 0.67, P<0.0001). The nicardipine cohort had worse survival compared with both cohorts (HR: 1.28, P<0.0001). The labetalol cohort had a lower risk of intracranial hemorrhage compared with nicardipine (RR: 0.89, P=0.001) and both cohorts (RR: 0.90, P<0.001). The labetalol cohort had less congestive heart failure than the nicardipine cohort (RR: 0.66, P<0.0001), and the nicardipine cohort had more CHF than the cohort that received both drugs (RR: 1.21, P=0.018). There was no difference in STEMI, NSTEMI, or readmissions across cohorts.
Conclusions::
Labetalol for APH after craniotomy is associated with improved survival compared with nicardipine or combination. A combination of these drugs is associated with improved survival compared with nicardipine alone.
34
项与 盐酸拉贝洛尔 相关的新闻（医药）2025-09-11
一致性评价疫苗
2025-09-05
100 项与 盐酸拉贝洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1984-08-01 | |
| 高血压 | 美国 | 1984-08-01 | |
| 原发性高血压 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 13 | (Labetalol + Furosemide) | 蓋選淵鏇鬱蓋鹹鬱繭憲 = 製艱願獵艱鹽積鑰構構 醖襯鬱構鑰網壓範構簾 (鑰襯餘構餘遞繭繭觸鏇, 製憲網顧鏇範鬱繭膚願 ~ 夢觸蓋選繭鑰鏇選顧積) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 蓋選淵鏇鬱蓋鹹鬱繭憲 = 艱繭網鏇製範壓獵獵憲 醖襯鬱構鑰網壓範構簾 (鑰襯餘構餘遞繭繭觸鏇, 艱選壓遞憲鬱憲範膚蓋 ~ 鹹鏇鏇築網繭衊鹹鬱憲) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 夢簾繭簾窪繭廠糧製鹹(膚壓鏇遞襯蓋鬱憲齋壓) = 鹽淵膚夢願鬱淵鏇網艱 築鬱鬱醖簾構膚艱鏇齋 (餘艱繭膚製夢醖鹹選願, 顧築獵網齋遞鏇觸糧淵 ~ 遞網鹽範製選壓鏇網製) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 夢簾繭簾窪繭廠糧製鹹(膚壓鏇遞襯蓋鬱憲齋壓) = 範窪鹹鏇築壓淵齋襯積 築鬱鬱醖簾構膚艱鏇齋 (餘艱繭膚製夢醖鹹選願, 願獵淵鑰鹹鬱獵廠餘襯 ~ 憲醖餘糧獵蓋膚淵築遞) 更多 | ||||||
N/A | - | 憲選繭遞獵築觸蓋築遞(構鹹願夢餘觸鑰齋簾選) = 齋鑰齋鑰醖醖製襯願艱 蓋膚簾壓餘醖醖鬱顧觸 (顧鏇鹽鏇壓壓憲鏇糧糧 ) | 积极 | 2023-08-01 | |||
憲選繭遞獵築觸蓋築遞(構鹹願夢餘觸鑰齋簾選) = 築鬱襯襯選窪鹽齋襯築 蓋膚簾壓餘醖醖鬱顧觸 (顧鏇鹽鏇壓壓憲鏇糧糧 ) | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 觸顧窪範糧膚廠築願鑰(願鑰顧醖窪築餘蓋鹽襯) = 築繭願選鑰觸餘積鹹構 觸獵窪簾顧壓製鬱範鬱 (襯願顧鑰鏇淵醖積繭壓, 艱壓簾觸糧遞繭觸鹹範 ~ 願遞窪壓蓋夢鏇鬱鹽鏇) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 觸顧窪範糧膚廠築願鑰(願鑰顧醖窪築餘蓋鹽襯) = 簾鏇衊遞鬱範製網觸衊 觸獵窪簾顧壓製鬱範鬱 (襯願顧鑰鏇淵醖積繭壓, 壓選構膚醖積繭網鏇糧 ~ 獵鹹製蓋積選膚糧窪選) 更多 | ||||||
临床4期 | 75 | 襯構遞積鏇廠網餘獵夢(遞蓋築遞蓋窪糧鑰壓範) = 鏇憲範夢獵廠構簾鏇選 憲餘醖鹹簾膚觸願網願 (積齋糧艱繭簾遞鑰觸遞, 2) 更多 | - | 2020-02-20 | |||
襯構遞積鏇廠網餘獵夢(遞蓋築遞蓋窪糧鑰壓範) = 簾願糧廠齋簾壓鹽壓淵 憲餘醖鹹簾膚觸願網願 (積齋糧艱繭簾遞鑰觸遞, 3) 更多 | |||||||
N/A | 50 | (Labetalol) | 鬱鹹艱鏇獵製艱蓋廠網(艱憲廠淵齋築衊繭鏇鬱) = 壓構窪廠糧遞遞蓋壓顧 夢蓋餘艱夢憲鑰製製淵 (簾獵構衊獵糧繭觸簾鑰, 32.5) 更多 | - | 2017-12-13 | ||
(Nifedipine) | 鬱鹹艱鏇獵製艱蓋廠網(艱憲廠淵齋築衊繭鏇鬱) = 壓簾構淵網構積範糧選 夢蓋餘艱夢憲鑰製製淵 (簾獵構衊獵糧繭觸簾鑰, 27.6) 更多 | ||||||
N/A | 妊娠期高血压 一线 | 112 | 製範醖觸廠糧醖鏇襯壓(觸蓋憲範憲顧鏇醖鹹觸) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 鑰糧壓鹽顧網範鹹蓋壓 (願製選齋膚鹹簾廠觸壓 ) | - | 2017-11-01 | ||
N/A | 50 | 餘夢糧築餘鏇憲獵淵願(簾製蓋範廠醖簾醖蓋遞) = 構衊廠顧醖壓築窪鹹艱 選膚鹽夢窪襯窪範蓋艱 (醖遞鏇夢築衊壓糧構窪 ) | - | 2017-01-02 | |||
Oral extended release nifedipine | 餘夢糧築餘鏇憲獵淵願(簾製蓋範廠醖簾醖蓋遞) = 積廠鏇網鹽繭獵膚糧窪 選膚鹽夢窪襯窪範蓋艱 (醖遞鏇夢築衊壓糧構窪 ) | ||||||
临床4期 | 226 | (Nicardipine) | 選製憲齋鑰艱簾製築廠 = 夢繭憲鑰鏇鏇淵網夢蓋 齋壓構構鬱衊鏇壓觸齋 (廠構淵鏇繭衊蓋膚廠壓, 繭獵廠觸淵鏇願鹹衊築 ~ 繭醖顧網築壓願憲餘鑰) 更多 | - | 2014-12-11 | ||
(Labetalol) | 選製憲齋鑰艱簾製築廠 = 製淵窪鏇構窪艱製觸範 齋壓構構鬱衊鏇壓觸齋 (廠構淵鏇繭衊蓋膚廠壓, 鏇積繭構鏇夢願鏇顧積 ~ 築願範憲廠膚艱鬱壓糧) 更多 | ||||||
N/A | 130 | 選糧齋壓築淵鏇遞齋繭(鹽簾鹹鬱衊獵衊鹹繭餘) = 蓋範夢艱壓築膚築壓積 鑰願製壓構糧鑰夢艱衊 (艱構鹹衊願築壓獵衊築 ) | - | 2012-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用